© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
Author | Elisabetta Landucci, MD
Articles
New Combinations With Epirubicin in Advanced Breast Cancer
May 01, 2001
ByPierfranco Conte, MD|Alessandra Gennari, MD|Elisabetta Landucci, MD|Valentina Guarneri, MD|Sara Donati, MD|Barbara Salvadori, MD|Carmelo Bengala, MDSeveral trials have shown that anthracyclines and taxanes can be combined to achieve response rates ranging from 70% to 90%, with complete responses ranging from 19% to 41%. In an attempt to increase the activity while
Epirubicin/Taxane Combinations in Breast Cancer: Experience From Several Italian Trials
May 01, 2001
ByPierfranco Conte, MD|Alessandra Gennari, MD|Valentina Guarneri, MD|Elisabetta Landucci, MD|Sara Donati, MD|Barbara Salvadori, MD|Carmelo Bengala, MD|Editta Baldini, MDDoxorubicin/paclitaxel (Taxol) combinations are very active in advanced breast cancer, with objective response rates up to 90%, but have shown a high incidence of cardiotoxicity. A phase I/II trial replacing